New broad-spectrum antibacterial study: I assume compound 30 is Brilacidin?
In this study, the synthesis and biological evaluation of cationic amphiphilic phenothiazine-based derivatives were reported. Among them, the most promising compound 30 bearing a n-heptyl group and two arginine residues displayed potent bactericidal activity against both Gram-positive (MICs?=?1.56?µg/mL) and Gram-negative bacteria (MICs?=?3.125–6.25?µg/mL). Compound 30 showed low hemolysis activity (HC50?=?281.4?±?1.6?µg/mL) and low cytotoxicity (CC50 > 50?µg/mL) toward mammalian cells, as well as excellent salt resistance. Compound 30 rapidly killed bacteria by acting on the bacterial cell membrane and appeared less prone to resistance. Importantly, compound 30 showed potent in vivo efficacy in a murine model of bacterial keratitis. Hence, the results suggested compound 30 has a promising prospect as a broad-spectrum antibacterial agent for the treatment of drug-resistant bacterial infections.
Several promising host defense peptide mimetics, such as Brilacidin, have alleviated some of the intrinsic shortcomings of CAMPs, Brilacidin passed the phase II trial for the treatment of acute skin and skin structure infections caused by Staphylococcus aureus
Unfortunately, I can't read the full study, but Brilacidin fits the description to a T. Can someone with access confirm that Brilacidin is indeed compound 30 in this enthusiastic study? I know that team had a previous study on Brilacidin as well.
Market Data 
Markets 
AI
